Chicago Equity Partners’s Array Biopharma Inc ARRY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-152,795
Closed -$7.08M 1022
2019
Q2
$7.08M Buy
152,795
+34,650
+29% +$973K 0.32% 70
2019
Q1
$2.88M Buy
+118,145
New +$2.46M 0.11% 248
2018
Q3
Sell
-103,465
Closed -$1.74M 928
2018
Q2
$1.74M Buy
103,465
+3,165
+3% +$50.3K 0.05% 415
2018
Q1
$1.64M Buy
+100,300
New +$1.61M 0.05% 415
2017
Q4
Sell
-220,907
Closed -$2.72M 872
2017
Q3
$2.72M Sell
220,907
-62,760
-22% -$583K 0.09% 310
2017
Q2
$2.37M Sell
283,667
-129,863
-31% -$1.06M 0.06% 340
2017
Q1
$3.7M Sell
413,530
-119,470
-22% -$1.27M 0.11% 208
2016
Q4
$4.68M Buy
533,000
+47,220
+10% +$347K 0.12% 175
2016
Q3
$3.28M Sell
485,780
-69,110
-12% -$267K 0.09% 216
2016
Q2
$1.98M Buy
554,890
+544,700
+5,345% +$1.78M 0.06% 272
2016
Q1
$30K Hold
10,190
﹤0.01% 576
2015
Q4
$43K Sell
10,190
-190
-2% -$867 ﹤0.01% 579
2015
Q3
$47K Buy
+10,380
New +$61.5K ﹤0.01% 556
2014
Q1
Sell
-12,575
Closed -$63K 505
2013
Q4
$63K Sell
12,575
-225
-2% -$1.23K ﹤0.01% 412
2013
Q3
$79K Buy
+12,800
New +$76K ﹤0.01% 431

Other funds holding ARRY

Chicago Equity Partners's ARRY Position: Q3 2019 in Review

Chicago Equity Partners sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 152,795 shares — an estimated $7.08M sold.

Chicago Equity Partners first reported a position in ARRY in Q3 2013 and held it in 15 quarters. The position peaked at $7.08M in Q2 2019. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.

  • Chicago Equity Partners reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
  • Chicago Equity Partners sold 152,795 Array Biopharma Inc shares in Q3 2019, an estimated $7.08M.
  • Chicago Equity Partners first reported a position in Array Biopharma Inc in Q3 2013 and held it in 15 quarters.
  • Chicago Equity Partners's Array Biopharma Inc position peaked at $7.08M in Q2 2019.
  • 1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.

Based on Chicago Equity Partners's 13F filing for Q3 2019, filed 30 Oct 2019.